SHORT VIDEO SUMMARIZING OUR GAME CHANGING TECHNOLOGY OUR - PowerPoint PPT Presentation

SHORT VIDEO SUMMARIZING OUR GAME CHANGING TECHNOLOGY

OUR MARKETS(PLATELETS,RED CELLS,CONTAMINATES, NO WASHING, NEW PROTECTANT) ELIMINA MINATION ON OF BLOOD D SHOR ORTAGES GES GLOBA BALL LLY Resea search and disco scovered ed in the sixtie ies s under er Militar itary Contr tract t with h Un Union on Car arbi bide e to elimin minat ate e shelf lf life e of Red d Cells. lls. Since e then we have e taken en it from om Red d Cell lls to Platele elets (shelf elf life e 5-6 days and d $30-50 50B B Market), ), White e Cells, ls, and Plasm sma. a. We can an impl mpleme ement t the Platele elet t market with thin in months hs using the existin sting cryo-protec ectant tant for bloo ood/s d/stem em cells. lls. Introd oducin ing a new w Cryo-protec ectan tant t that is alread ady FDA approved d for ot other er consu sumab mable le produc oducts. s. This s new w Cryo-Protec ectant tant will ll elimin minat ate e the need ed to be remo moved ed prior or to use. . The wa wash shing ing is an expen ensiv sive e toxic ic proc ocess ess whic ich will ll save e hospital itals/ s/blo blood od centers s millio lions. s. Our proc ocess ss will ll also so elimin minat ate e most st if not ot all contamin taminat ates es in bloo ood/s d/stem em cells, lls, i.e. . bac acter eria ia, parasit asites, es, HeP A-C, C, and Viruse ses. . We will ll strea eam m line the whole ole donatio ation and managem agement t proc ocess ss. . All you do is donat ate e bloo ood. d. No separ arate e proc ocess ss to extr trac act t Platele elets, ts, White e Cells lls, , or Plasm sma. a. Significa icant t savi vings to hospital ital/b /bloo lood d cen enter ers. s.

Strat ateg egic ic partnerin ing will ll be with th com ompan anie ies like: e: Zipli line.c e.com. m. They use Drones ones for deliv livery of blood ood in Afric ica within in minutes es vs hours s and d days. s. Fremon emont Scie ientif tific ic has a devic ice and inven entor ory managem agemen ent system em and a portab table le devi vice (cos ost t approx. . &5K) ) that is no wa water er base se and d portab table. le. In most st if not ot all case ses s the custome omer has the req equir ired ed free eezer ers s thereb eby eliminati iminating any majo jor cap apital ital investm estmen ent to impl mpleme ement t our techn hnolo ology. Ther ereb eby savi ving millio lions s in re-curing cost osts. s. day . . This s is game me changi anging techn hnolo ology that will l chan ange blood ood managem agemen ent as we know w it toda

CURRENT MARKET ECONOMICS The market s which the process will have a major impact on: 1. Elimination of shelf life for all blood components: currently a $5.0B market 2. Elimination of shelf of platelets: currently a $3.0B market 3. Elimination of washing of cryoprotectant from blood and stem cells: potentially a $5B market

5 YEAR R FINANCIA ANCIAL L PROJECTION JECTIONS C-Levelclone Financial Statement (Platelets/New Protectant) 2020 2021 2022 2023 2024 Revenue 296,345,670 325,980,237 358,578,261 394,436,087 433,879,695 CC/G/S 88,903,701 97,794,071 107,573,478 118,330,826 130,163,908 Gross Margins 207,441,969 228,186,166 251,004,783 276,105,261 303,715,787 Operating Income Expenses 2,569,234 2,826,157 3,108,772 3,419,649.00 3,761,615 Profit Before Taxes 204,872,735 225,360,009 247,896,011 272,685,612.00 299,954,172

MARKE KET T SIZE ZE MODEL EL A PLATEL TELETS ETS UNITS TS DISOP SOPOSED OSED OF US (2011) ) 650,000 00 FMV of each h unit ($625) Value e of dispos osed d units( s(20 2011) 1) $406, 6,25 250, 0,00 000 Global al Market t $4,062, 2,500, 00,000 00 Global al Market t forward value ue 2020 ( growth th @ 2.5%PA) A) $482,903 03,587, 7,000 Assume ume 25% of Market

MA MARKE KET T SIZE ZE MODE DEL L A PLATELE TELETS TS Assume ume CL CLC C @25% of the market et $1, 1,121,05 059, 9,96 967 Royalty ty @10% $112,105, 05,997

MARKET ET SIZE E Model el B New w Prot otecta ctant nt Becker’s Hospital Review Hospit ital al rankings ngs by size ize # 1 w/ 2272 beds $74,248, 8,36 366 #100 w/674 4 beds ds $22,026, 26,144 #27 w/Joh ohn n Hopkins ns w/918 beds $ 30,000, 0,00 000 Mean n budge get t (1 and 100) $ 48,13 137, 7,255 55 US Blood od Mgt t budg dget et top 100 hospi pita tals s US $4,813, 3,725, 25,490 90 (the e data for the Platele elets ts and d New Prot otecta ctant nt taken en from the National ional Blood od Collecti ection on Utilization ization Repo port

Market t Size Discoun count t by 2/3 = reminder der 1/3 $ 1. 1.602, 2,970, 70,588 CLC process cess saving ng @ 15% $ 240,445, 45,588 88 Global alize ize @ 4 times es $961, 1,78 782, 2,35 352, 2,940 940 Process ess Royaltie alties s @7.5% % $ 72,13 133, 3,67 676 Tot otal al Roya yalti ties es Annual ally y $18 184,23 239, 9,67 673

BLOOD STORAGE DURATION & ADVERSE OUTCOMES IN CARDIAC SURGERY Clevela land nd clini nic c (Dr.Col Colle lenn nn Gorman n Koch) conduct ucted d the largest est blood storag orage e study udy to date . They found nd blood stored red more than n 14 days s are most t likely y to suffer r post t operati tive comp mplica cati tion n https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=0jF7k =0jF7kbIc6_ c6_M

KEY TAKE AWAYS • The technology is patented • The cryoprotectant used in the technology is currently FDA approved for other “HUMAN –INGESTED” consumable products • The cryoprotectant will replace DMSO/Glycerol which are the current standard protectants in use, each with significant documented disadvantages • The cryoprotectant is less expensive to purchase and the ratio of cryorotectant to be used is dramatically less (we estimate a reduction 400X’s in the amount required over current protocol) • Hospital and blood centers already have equipment to implement process. NO ADDITIONAL CAPITAL OUTLAY • Dramatic cost savings to hospital and blood centers (Data taken from ARC/WHO and National Blood Collection and Utilization Survey Report)

NATURAL DISASTERS /STORMS ON BLOOD SUPPLY Natural ral disast saster ers, s, storms orms have a m major impact mpact on the supply pply ava vailable. Our technol nology gy will eliminat minate shelf f life https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=Ze =Zet0vi t0viZ8a 8aVI

CREATING PLATELETS FROM BONE MARROW It is expensiv nsive e comp mplicat cated d and not ot alwa ways ys ava vailable. Our process ess you just st donate e blood with th our patent nted d Heat/Transf nsfer er rate. e. https tps://ww //www.youtu utube.c .com/w m/watch? atch?v=ZX =ZXLLP LPWa9G 9Grg rg

CRYOPRESERVATION TECHNOLOGY WHAT ARE THE KEY DIFFERENCES IN CLC’S PROCESS COMPARED TO THE CURRENT STANDARD PROTOCOL? The specialty cryoprotectant used in this patented process is fundamentally different than currently used organic cryoprotectants (Glycerol and DMSO) and has the following distinct and unique characteristics: • It is a polymer, not organic, and therefore readily available and economically advantaged • It works at dramatically reducing quantums – for example, 400 times less than the currently used amount of Glycerol/DMSO • Critically, unlike current cryoprotecants , it does not need to be “washed” from the blood prior to transfusion, thereby eliminating an entire step in the commercial process of utilizing cryopreserved blood

"Ice Recrystallisation Inhibition(IRI)- This slide highlights the core "activity" of our polymers, which is to slow the rate of ice crystal growth. Left figure shows ice crystals grown from PBS buffer for 30 minutes, Middle figure shows ice crystals grown from PBS with the addition of PEG which has no "antifreeze" activity. Right shows the same as above but with our patented cryo-protectant which has clearly stopped the ice crystals from growing.”

Our Value e Proposi positi tion on Eliminate shelf life of all components of blood Draw blood as usual no separate station for Platelets No Glycerol which must be washed before use No DMSO which must be washed out before use New Protectant- Polyvinyl Alcohol(PVA) FDA approved for other consumable products and will not have to washed prior to use Store whole blood until ready for use Eliminate shortages for all components Globally

AMERIC RICAN N ACADE DEMY MY OF BLOOD OOD BANKING KING PUBLIS ISHED HED IN 12-25 25-2016

WHAT IS CLC’S PROPRIETARY TECHNOLOGY? • Revolutionary advance in the science of cryopreservation of blood and its component parts, including platelets, using a proprietary process that is commercially feasible and economically superior to methods currently used in the United States and Europe • Significantly enhances the science of organ preservation and handling, thereby vastly improving the process of transplantation • Potentially broader and economic applicability to the current commercially utilized preservation process of high-end foods